VistaGen Therapeutics awarded $3,700,000 NIH Drug Development Grant for lead epilepsy drug candidate

Vistagen Therapeutics, Inc. announced that the National Institute of Neurologic Disorders and Stroke (NINDS), a division of the U.S. National Institutes of Health (NIH), has awarded the company a $3,700,000 grant entitled “Preclinical Development of 4-Cl-KYN to Treat Epilepsy.

Source: Vistagen Therapeutics, Inc.